Summit Therapeutics (SMMT) has withdrawn its proposed underwritten public offering of securities, due to market conditions, the company said in a Thursday regulatory filing.
The company had announced the launch of an underwritten public offering of $500 million of its common stock on Tuesday.
Price: $13.49, Change: $+0.43, Percent Change: +3.33%